Annexin Pharmaceuticals AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.annexinpharma.com
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Annexin Pharmaceuticals AB
- Target Recruit Count
- 16
- Registration Number
- NCT05532735
- Locations
- 🇺🇸
Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States
🇺🇸Eye Associates of Northeast Louisiana, West Monroe, Louisiana, United States
🇺🇸Tulsa Retina Consultants, Tulsa, Oklahoma, United States
First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Other: PlaceboBiological: ANXV
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Annexin Pharmaceuticals AB
- Target Recruit Count
- 46
- Registration Number
- NCT04850339
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
© Copyright 2025. All Rights Reserved by MedPath